Verve Therapeutics Inc (VERV)
4.79
-0.59
(-10.97%)
USD |
NASDAQ |
Nov 15, 16:00
4.79
0.00 (0.00%)
After-Hours: 20:00
Verve Therapeutics Free Cash Flow (Quarterly): -40.54M for Sept. 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -40.54M |
| June 30, 2024 | -35.14M |
| March 31, 2024 | -43.52M |
| December 31, 2023 | -42.86M |
| September 30, 2023 | -12.87M |
| June 30, 2023 | -50.62M |
| March 31, 2023 | -52.47M |
| December 31, 2022 | -37.86M |
| September 30, 2022 | -31.81M |
| June 30, 2022 | -29.48M |
| Date | Value |
|---|---|
| March 31, 2022 | -36.42M |
| December 31, 2021 | -29.02M |
| September 30, 2021 | -22.36M |
| June 30, 2021 | -14.65M |
| March 31, 2021 | -16.21M |
| December 31, 2020 | -15.93M |
| September 30, 2020 | -7.346M |
| June 30, 2020 | -7.54M |
| March 31, 2020 | -7.875M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-52.47M
Minimum
Mar 2023
-7.346M
Maximum
Sep 2020
-28.13M
Average
-29.48M
Median
Jun 2022
Free Cash Flow (Quarterly) Benchmarks
| Ardelyx Inc | 0.364M |
| Biomarin Pharmaceutical Inc | 200.30M |
| Sage Therapeutics Inc | -82.36M |
| ALX Oncology Holdings Inc | -25.52M |
| Immuneering Corp | -11.56M |